Andere talen Mabwell (Shanghai) Bioscience Co., Ltd.

Aandelen

688062

CNE100005RD2

slotkoers Shanghai S.E. Andere beurzen 00:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
28,94 ^CNY	-1,53%		-11,15%	-11,47%

24/05	Mabwell kondigt klinische gegevens van 9MW2821 aan	CI
13/05	Mabwell kondigt de voortgang aan van het klinische onderzoek naar 9MW2821 voor triple-negatieve borstkanker	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Mabwell Announces 9MW2821 Clinical Data	24/05
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer	13/05
Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821	07/05
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China	08/04
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment	04/04
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting	19/03
Mabwell Scraps Licensing Deal With Yangtze River Pharma	27/02
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology	21/02
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711	20/02
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5%	19/02
Certain A-Shares of Mabwell Bioscience Co., Ltd. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	18/01
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA	19/12
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial	11/12
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug	08/12
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs	23-10-23
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	18-10-23
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor	28-09-23
Mabwell Bioscience Co., Ltd.(XSSC:688062) added to S&P Global BMI Index	18-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Mabwell (Shanghai) Bioscience Co., Ltd.

Aandelen

688062

CNE100005RD2

Andere talen

Filters